Navigation Links
PSA Test Losing Diagnostic Value, Study Says
Date:3/10/2008

Advances in biopsy techniques rendering prostate cancer screen less useful, but some experts disagree

MONDAY, March 10 (HealthDay News) -- Changes in medical practice have undermined the value of the prostate-specific antigen (PSA) test as a diagnostic tool for prostate cancer, a new study asserts.

However, that assertion was immediately challenged by other experts in the field.

The American Cancer Society recommends annual screening for prostate cancer for most men after age 50. The screening is done in two steps: a digital rectal exam, followed by a blood test for PSA, a protein produced by the prostate gland.

"In men with an abnormal digital rectal examination, it [the PSA test] still is very predictive," said study author Dr. Douglas S. Scherr, clinical director of urological oncology at Weill Cornell Medical Center in New York City. "For men with a normal digital rectal examination, it has lost the predictive accuracy it had in the 1990s."

For those men, exact PSA readings matter less, because doctors are doing more biopsies now and are using improved biopsy techniques, Scherr explained. His report was expected to be published in the April 15 issue of Cancer. In a retrospective analysis, his team looked at 1,607 prostate biopsies performed at Weill Cornell between 1993 and 2005, and uncovered several trends.

In the 1990s, biopsies generally were limited to men with PSA readings higher than 4 nanograms per milliliter of blood. Later, they were often done when the PSA levels were between 2.5 and 4, Scherr said.

"In the early and mid-90s, we used six needles when we did a biopsy," he said. "Now, we stick in 14. Taking more cores and doing biopsies at lower PSA levels has allowed us to keep the prostate cancer detection level steady. If we kept the PSA level at 4 rather than at 2.5, the cancer detection rate would have fallen rapidly."

Increased awareness of prostate cancer has also changed the screening picture, Scherr said. "You almost never have an abnormal rectal examination these days," he said.

There is a need to develop new biomarkers for prostate cancer beyond PSA, Scherr said. "Should a man when he turns 50 have a biopsy?" he said. "It is certainly an important question that needs being looked at."

But the study merely "makes a statistical point about an unusual population," said Andrew Vickers, a statistician whose title at Memorial Sloan-Kettering Cancer Center in New York is attending research methodologist.

"It apples to men who have regular screening," Vickers said. "It doesn't apply to men who haven't been screened. For those men, the PSA test might be more accurate."

And the study is misleading because of information it doesn't contain, said Dr. Ian M. Thompson, chairman of urology at the University of Texas Health Science Center at San Antonio.

The study includes only men on whom biopsies were done, Thompson said. "If you don't biopsy something, you don't know if you have cancer or not," he said. "The study is informative only of men who had biopsies. There is nothing in it about the criteria they used to recommend biopsies."

Risk factors for prostate cancer, such as ethnicity, age and family history, are not mentioned in the study, Thompson added. "You don't know anything about the people in their practice who never had a biopsy," he noted.

The PSA test has flaws, Thompson acknowledged. Most notably, it is unable to distinguish between prostate cancers that will grow so slowly that they do not endanger life and those that are aggressive enough to kill.

"But of all the tools we currently have, the PSA test is valuable," he said. "People dealing with other kinds of cancer wish they had a blood test like PSA."

More information

You can learn about the diagnosis and treatment of prostate cancer from the National Cancer Institute.



SOURCES: Douglas S. Scherr, M.D., clinical director, urological oncology, Weill Cornell Medical Center, New York City; Andrew Vickers, Ph.D., statistician, Memorial Sloan- Kettering Cancer Center, New York City; Ian M. Thompson, chairman, urology, University of Texas Health Science Center, San Antonio; April 15, 2008, Cancer


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe)
2. IRIDEX Announces Closing of $5.0 Million Private Placement
3. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
4. Cruel Deaths in Mexico a Result of Closing U.S. Horse Processing Plants: AVMA
5. Bionovo Announces Closing of Public Offering of Common Stock
6. PA Residents Losing Employer Coverage at Rate Second Only to CA
7. Physicians Hail VNUS Device for Closing Diseased Perforating Veins
8. Biopure Announces Closing of $14.9 Million Financing
9. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
10. AMICAS Solutions Closing the Loop in Radiology Communications
11. Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PSA Test Losing Diagnostic Value, Study Says
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
Breaking Medicine Technology: